Former Allergan CEO David Pyott will not get a seat on the board at Actavis after all, now that their $70 billion merger is done.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1MJW8ut
Cap comentari:
Publica un comentari a l'entrada